Blood clues: could two proteins reveal how diabetes harms kidneys?
NCT ID NCT07749664
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study looks at whether two blood markers—DEL-1, an anti-inflammatory protein, and thromboxane A2, a sign of platelet activity—are linked to diabetic nephropathy, a common kidney complication of diabetes. Researchers will measure these markers in 80 adults, including patients with diabetic nephropathy and healthy controls, to see if they relate to disease severity. The goal is to explore whether these markers could serve as indicators for diagnosis or tracking the disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If certain blood markers are linked to diabetic kidney disease severity, they could become tools for earlier diagnosis or monitoring.
- What could go wrong
- This is a small observational study, so it can only show associations, not cause and effect. The findings may not lead to practical tests or treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will include adult participants aged 18 to 70 years, recruited from Aswan University Hospital. The study will consist of patients diagnosed with diabetic nephropathy based on clinical and laboratory criteria, in addition to a group of age- and sex-matched healthy controls. Patients with diabetic nephropathy will be enrolled regardless of disease stage to allow assessment of biomarker variation across different levels of disease severity. All participants will undergo clinical evaluation and laboratory investigations. Participants with significant comorbid conditions that may affect inflammatory status or platelet function will be excluded to minimize confounding factors.
- Ages
-
18 to 70 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients aged between 18 and 70 years. * Patients diagnosed with diabetic nephropathy based on clinical and laboratory findings. * Patients undergoing evaluation or follow-up for diabetic kidney disease. * Ability and willingness to provide informed consent. Exclusion Criteria: * \- Patients with known hepatic disease. * Patients with significant cardiovascular disease. * Patients with malignancy. * Patients who have undergone recent surgery. * Patients with known hematological disorders or hypercoagulable states. * Patients receiving medications that significantly affect platelet function.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nephropathy, diabetic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.